Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675661 · ClinicalTrials.gov registry record · Phase 3
Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment
A Phase 3 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT01675661 is a Phase 3 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 302 participants.
The verdict
NCT01675661, a Phase 3 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).
Interventions
- DRUG Placebo
- DRUG N-Acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01675661
The ClinicalTrials.gov registry entry for NCT01675661 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01675661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01675661 about?
NCT01675661 is a clinical study titled "Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment". The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).
What is the current status of trial NCT01675661?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2014-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01675661?
The interventions under investigation include: Placebo (DRUG), N-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT01675661?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.